Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

Haejin In; Olga Kantor; Susan M. Sharpe; Marshall S. Baker; Mark S. Talamonti; Mitchell C. Posner

doi:10.1245/s10434-015-5075-1

Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

Haejin In, Olga Kantor, Susan M. Sharpe, Marshall S. Baker, Mark S. Talamonti, Mitchell C. Posner

Surgery

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

Original language	English (US)
Pages (from-to)	1-7
Number of pages	7
Journal	Annals of Surgical Oncology
DOIs	https://doi.org/10.1245/s10434-015-5075-1
State	Accepted/In press - Jan 11 2016

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1245/s10434-015-5075-1

Cite this

@article{72ee82d99f704f4a81c537d34374c63c,

title = "Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy",

abstract = "Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.",

author = "Haejin In and Olga Kantor and Sharpe, {Susan M.} and Baker, {Marshall S.} and Talamonti, {Mark S.} and Posner, {Mitchell C.}",

year = "2016",

month = jan,

day = "11",

doi = "10.1245/s10434-015-5075-1",

language = "English (US)",

pages = "1--7",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer New York",

}

TY - JOUR

T1 - Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

AU - In, Haejin

AU - Kantor, Olga

AU - Sharpe, Susan M.

AU - Baker, Marshall S.

AU - Talamonti, Mark S.

AU - Posner, Mitchell C.

PY - 2016/1/11

Y1 - 2016/1/11

N2 - Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

AB - Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84954176445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954176445&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-5075-1

DO - 10.1245/s10434-015-5075-1

M3 - Article

C2 - 26753752

AN - SCOPUS:84954176445

SN - 1068-9265

SP - 1

EP - 7

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

ER -

Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this